These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11850206)

  • 21. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
    Tekmal RR; Kirma N; Gill K; Fowler K
    Endocr Relat Cancer; 1999 Jun; 6(2):307-14. PubMed ID: 10731124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
    Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
    Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
    Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
    Ellis MJ; Rosen E; Dressman H; Marks J
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):301-7. PubMed ID: 14623525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
    Miller WR; Dixon JM; Cameron DA; Anderson TJ
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):103-7. PubMed ID: 11850213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors and their application in breast cancer treatment*.
    Brodie AM; Njar VC
    Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Endocrine therapy of causation: role of aromatase inhibitors in breast cancer].
    Longo F; Mansueto G
    Tumori; 2003; 89(6):21-8. PubMed ID: 14870836
    [No Abstract]   [Full Text] [Related]  

  • 35. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
    Richards JA; Petrel TA; Brueggemeier RW
    J Steroid Biochem Mol Biol; 2002 Feb; 80(2):203-12. PubMed ID: 11897504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.